Skip to main content
Premium Trial:

Request an Annual Quote

DOE Gives Genelabs $4.8M For Pathogens Research

Premium

REDWOOD CITY, Calif.--Biopharmacauetical company Genelabs Technologies will receive $4.8 million to fund its second year of genomics-based research for the US Defense Advanced Research Projects Agency, the research arm of the US Department of Defense. The funding is a 25 percent increase over what Genelabs received in 1998 under the agency's Unconventional Pathogen Countermeasures Program. Genelabs will use the money to apply its platform technologies, which create drugs that function by binding to DNA or double-stranded RNA, to develop pharmaceutical countermeasures to biological warfare agents.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.